Search

everythinglearnresearchcommunity

for

Search:↓

EGCG may help treat alopecia areata by blocking certain immune responses and reducing specific harmful immune cells.

BTNL2 helps protect hair follicles from immune attacks.

Dogs have a skin condition like human pseudopelade, causing hair loss that doesn't improve with treatment.

iNKT cells can help prevent and treat alopecia areata by promoting hair regrowth.

Alopecia areata is an autoimmune disease where T cells attack hair follicles.

Restoring hair follicle immune privilege may help treat alopecia areata.

Alopecia areata involves specific immune cells, offering potential treatment targets.

ILC1-like cells can cause alopecia areata by attacking hair follicles.

Innate lymphoid cells type 1 may contribute to alopecia areata by damaging hair follicles.

Alopecia areata involves both innate and adaptive immunity, with specific genes linked to the disease.

Androgenetic alopecia involves immune cell disruptions, especially increased CD4+ T cells around hair follicles.

Diphencyprone treatment increases CD8 lymphocytes in the scalp, which is associated with hair regrowth in alopecia areata patients.

Diffuse alopecia areata involves more inflammation and higher allergy-related antibodies than patchy types.

Vitamin B5 and coenzyme A may help regulate the immune system and could improve treatments for chronic diseases and cancer.

Antroquinonol may help prevent skin depigmentation by suppressing certain immune cells.

New treatments targeting T-cell pathways are needed for better alopecia areata management.

Blocking the CXCR3 receptor reduces T cell accumulation in the skin and prevents hair loss in mice.

Hair follicles may help teach the immune system to tolerate new self-antigens, but this can sometimes cause hair loss.

CD4 T cells need IFN-γ to cause hair loss in alopecia areata.

The TCL1 transgenic mouse model is useful for understanding human B-cell leukemia and testing new treatments.

BST2 is highly expressed in certain immune cells in alopecia areata, suggesting a role in the disease.

A new mouse model effectively mimics vitiligo for research and drug testing.

CD8+ T cells are involved in alopecia areata and may cause disease relapse.

SOCS3 treatment can prevent hair loss by stopping harmful immune responses.

RANKL improves the immune response against herpes simplex virus by enhancing T cell activation and could help develop better treatments or vaccines.

Understanding the immune-related causes of Alopecia Areata has led to potential treatments like JAK inhibitors.

Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.

Animal models have helped understand hair loss from alopecia areata and find new treatments.

Autoimmune hair loss may be linked to increased Th1 and Th17 cells and decreased Th2 cells.

Natural killer and CD8+ T cells play a key role in hair loss in androgenetic alopecia.